PMID- 18206542
OWN - NLM
STAT- MEDLINE
DCOM- 20080324
LR  - 20131121
IS  - 0165-4608 (Print)
IS  - 0165-4608 (Linking)
VI  - 180
IP  - 2
DP  - 2008 Jan 15
TI  - Translocation (2;11)(q37;q23) in therapy-related myelodysplastic syndrome after 
      treatment for acute promyelocytic leukemia.
PG  - 149-52
LID - 10.1016/j.cancergencyto.2007.10.003 [doi]
AB  - Treatment of acute promyelocytic leukemia (APL) with a combination of 
      anthracycline-based chemotherapy and all-trans retinoic acid (ATRA) leads to very 
      high rates of complete remission and survival. There are only a limited number of 
      publications on the development of therapy-related myelodysplastic syndrome (MDS) 
      or acute myeloid leukemia during follow-up of APL. Although drugs targeting at 
      DNA-topoisomerase II characteristically induce translocations involving 11q23, 
      this was seldom seen in patients treated for APL. We report on a patient 
      initially diagnosed with APL. Response to therapy was monitored by fluorescence 
      in situ hybridization (FISH) and reverse-transcriptase polymerase chain reaction 
      for the PML-RARalpha rearrangement. Consecutive samples showed a swift and 
      complete reduction of PML-RARalpha rearranged cells. Twenty months after 
      diagnosis, however, conventional cytogenetics revealed a complex karyotype with a 
      translocation involving 11q23 and loss of chromosomes 7q and Xq. FISH analysis 
      with the MLL probe identified 2q37 (harboring the SEPT2 gene) as the 
      translocation partner of chromosome 11. We consider the rather unique 
      t(2;11)(q37;q23) as the primary event causing therapy-related MDS in our patient. 
      This case stresses the importance of conventional karyotyping to be performed on 
      a regular basis in all treated APL patients for the early detection of 
      chromosomal aberrations that indicate the development of therapy-related MDS or 
      acute myeloid leukemia.
FAU - Snijder, Simone
AU  - Snijder S
AD  - Department of Clinical Genetics, Academic Medical Center, Meibergdreef 15, 1105 
      Amsterdam, The Netherlands. s.snijder@amc.uva.nl
FAU - Mellink, Clemens H M
AU  - Mellink CH
FAU - van der Lelie, Hans
AU  - van der Lelie H
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Cancer Genet Cytogenet
JT  - Cancer genetics and cytogenetics
JID - 7909240
RN  - 5688UTC01R (Tretinoin)
RN  - BZ114NVM5P (Mitoxantrone)
RN  - ZRP63D75JW (Idarubicin)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects
MH  - Cells, Cultured
MH  - *Chromosomes, Human, Pair 11
MH  - *Chromosomes, Human, Pair 2
MH  - Fatal Outcome
MH  - Female
MH  - Humans
MH  - Idarubicin/administration & dosage
MH  - Leukemia, Promyelocytic, Acute/*drug therapy/genetics
MH  - Middle Aged
MH  - Mitoxantrone/administration & dosage
MH  - Myelodysplastic Syndromes/*etiology/genetics
MH  - *Neoplasms, Second Primary
MH  - *Translocation, Genetic
MH  - Tretinoin/administration & dosage
EDAT- 2008/01/22 09:00
MHDA- 2008/03/25 09:00
CRDT- 2008/01/22 09:00
PHST- 2007/07/25 00:00 [received]
PHST- 2007/10/03 00:00 [revised]
PHST- 2007/10/04 00:00 [accepted]
PHST- 2008/01/22 09:00 [pubmed]
PHST- 2008/03/25 09:00 [medline]
PHST- 2008/01/22 09:00 [entrez]
AID - S0165-4608(07)00644-9 [pii]
AID - 10.1016/j.cancergencyto.2007.10.003 [doi]
PST - ppublish
SO  - Cancer Genet Cytogenet. 2008 Jan 15;180(2):149-52. doi: 
      10.1016/j.cancergencyto.2007.10.003.